An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

María Laura Acosta-Felquer, Javier Rosa, Enrique R SorianoRheumatology Unit, Internal Medical Services, and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α&nbs...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Acosta-Felquer ML, Rosa J, Soriano ER
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
certolizumab pegol
tumour necrosis factor alpha inhibitors
psoriatic arthritis
efficacy
safety.
Diseases of the musculoskeletal system
RC925-935
Acceso en línea:https://doaj.org/article/e03a92969113483db5c49e04601dd081
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares